RxDoctor Payments DataLook up a doctor →

Benjamin Weinberg, MD

Hematology & Oncology · Washington, DCNPI 1598064941

Payments from drug & device makers

$7,274,164in general payments, 2019–2025

Across 531 payments — averaging $13,699 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Biopharmaceuticals, Inc$4.2M
  • Merck$1.7M
  • E.r. Squibb & Sons, L.L.C.$308K
  • Pfizer$284K
  • Janssen Research & Development, LLC$146K
  • G1 Therapeutics, Inc.$101K
  • plus $580K from 29 others

What the payments were for

  • Consulting fees$44,00914%
  • Speaking & faculty fees$250,27777%
  • Travel & lodging$24,6058%
  • Food & beverage$6,5842%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,274,164 in reported general payments places this provider in the 95th percentile of 69 hematology & oncology providers in District of Columbia.

See all hematology & oncology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$65,078
Medicare patients
145
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sunitinib Malate13$168,997
LonsurfTrifluridine/Tipiracil Hcl12$81,610
Abiraterone Acetate12$67,019
CreonLipase/Protease/Amylase29$48,010
EliquisApixaban37$33,160
Morphine Sulfate ErMorphine Sulfate22$893
Oxycodone Hcl34$758
Prednisone19$222
Prochlorperazine Maleate22$182
Ondansetron Hcl23$136
Pantoprazole Sodium22$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Taiho Oncology, Inc.Lonsurf$36,601$81,61012 claims
PfizerEliquis$283,565$33,16037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 69 hematology & oncology providers in District of Columbia.

Other hematology & oncology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →